在伊马替尼治疗慢性骨髓增殖性疾病期间发生的骨髓纤维化，该疾病同时存在BCR-ABL易位和JAK2V617F突变。 - Suppr

Suppr

超能文献

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.

作者信息

Hussein Kais, Bock Oliver, Seegers Anna, Flasshove Michael, Henneke Felicitas, Buesche Guntram, Kreipe Hans Heinrich

出版信息

Blood. 2007 May 1;109(9):4106-7. doi: 10.1182/blood-2006-12-061135.

DOI:10.1182/blood-2006-12-061135

PMID:17449802

Abstract

摘要

相似文献

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.在伊马替尼治疗慢性骨髓增殖性疾病期间发生的骨髓纤维化，该疾病同时存在BCR-ABL易位和JAK2V617F突变。

Blood. 2007 May 1;109(9):4106-7. doi: 10.1182/blood-2006-12-061135.

Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.达沙替尼治疗对伊马替尼耐药的慢性粒细胞白血病患者时BCR/ABL1融合基因和JAK2V617F突变均消失

J Clin Exp Hematop. 2012;52(2):145-7. doi: 10.3960/jslrt.52.145.

Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.Jak2 1型抑制剂NVP-BSK805和NVP-BVB808对Jak2突变阳性和Bcr-Abl阳性细胞系的作用。

Acta Haematol. 2014;132(1):75-86. doi: 10.1159/000356784. Epub 2014 Jan 31.

[Chronic myeloid leukemia: up-to-date management].[慢性髓性白血病：最新治疗方法]

Rinsho Ketsueki. 2014 Jan;55(1):42-55.

[Clinical progress in chronic myelogenous leukemia].

Rinsho Ketsueki. 2009 Oct;50(10):1489-99.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.在停止伊马替尼治疗后疾病持续不可检测的慢性期慢性髓性白血病患者中，主要分子学反应缺失可作为重新开始酪氨酸激酶抑制剂治疗的触发因素。

J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.

Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy.

Am J Hematol. 2011 Jul;86(7):531-2. doi: 10.1002/ajh.22084. Epub 2011 Jun 14.

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.大多数接受伊马替尼治疗的患者达到了深度分子反应，该反应可预测生存，并且通过优化的高剂量伊马替尼更快实现：来自随机 CML-研究 IV 的结果。

J Clin Oncol. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2.

Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.来自印度的慢性髓性白血病患者中对伊马替尼疑似耐药的BCR-ABL激酶结构域突变谱——突变罕见且分布各异。

Leuk Lymphoma. 2009 Dec;50(12):2092-5. doi: 10.3109/10428190903332486.

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.慢性髓性白血病慢性期患者在长期接受伊马替尼治疗后改用尼洛替尼，达到深度分子反应。

Blood. 2014 Jul 31;124(5):729-36. doi: 10.1182/blood-2013-12-544015. Epub 2014 Jun 19.

引用本文的文献

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.同时存在JAK2 V617F和BCR::ABL1的患者的临床、形态学和遗传学特征

Sci Rep. 2025 Jul 18;15(1):26046. doi: 10.1038/s41598-025-11096-6.

Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patient.老年患者采用阿伐替尼与聚乙二醇干扰素α-2b联合治疗携带JAK2 V617F突变的慢性髓性白血病急变期取得成功

Int J Hematol. 2025 Apr 29. doi: 10.1007/s12185-025-03994-2.

Cytokine-induced killer cells: new insights for therapy of hematologic malignancies.细胞因子诱导的杀伤细胞：恶性血液病治疗的新见解。

Stem Cell Res Ther. 2024 Aug 13;15(1):254. doi: 10.1186/s13287-024-03869-z.

Co-occurrence of mutation and translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination.慢性骨髓增殖性肿瘤中突变与易位的同时出现：一种潜在的混淆性基因组合。

Front Oncol. 2024 Jan 12;13:1329298. doi: 10.3389/fonc.2023.1329298. eCollection 2023.

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.ASXL1 突变可预测慢性髓性白血病患者对尼罗替尼治疗的分子反应较差。

Leukemia. 2022 Sep;36(9):2242-2249. doi: 10.1038/s41375-022-01648-4. Epub 2022 Jul 28.

Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?对于同时患有骨髓纤维化和慢性粒细胞白血病（CML）的患者，异基因移植是一种选择吗？

Mediterr J Hematol Infect Dis. 2021 Nov 1;13(1):e2021062. doi: 10.4084/MJHID.2021.062. eCollection 2021.

Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches.血液系统恶性肿瘤的免疫治疗：新兴疗法和新方法。

Int J Mol Sci. 2020 Oct 27;21(21):8000. doi: 10.3390/ijms21218000.

Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.成功治疗一名同时存在Janus激酶2（JAK2）R795S突变和断点簇区域-ABL1（BCR-ABL1）融合的慢性粒细胞白血病患者：病例报告及文献综述

Am J Case Rep. 2020 Oct 6;21:e925151. doi: 10.12659/AJCR.925151.

Emergence of Chronic Myeloid Leukemia in a -V617F Polycythemia Vera.JAK2 V617F 真性红细胞增多症患者中慢性髓性白血病的出现

J Hematol. 2020 Apr;9(1-2):23-29. doi: 10.14740/jh591. Epub 2020 Apr 23.

Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review.伴有BCR-ABL1融合和CALR突变的非典型骨髓增殖性肿瘤：一例报告及文献复习

Medicine (Baltimore). 2020 Jan;99(5):e18811. doi: 10.1097/MD.0000000000018811.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验